RARE DISEASE
Classic stiff person syndrome
Classic stiff person syndrome
Classic stiff person syndrome
Synonyms: Classic SPS
Synonyms: Classic SPS
Synonyms: Classic SPS
Drug discovery
2
drugs
With orphan designations
Overview
Classic Stiff Person Syndrome (SPS) is a rare autoimmune neurological disorder characterized by progressive axial muscle rigidity, painful spasms triggered by sensory/emotional stimuli, and gait instability. Associated with glutamic acid decarboxylase (GAD-65) antibodies in ~80% of cases, it predominantly affects middle-aged women. Diagnosis combines clinical evaluation, GAD antibody testing, electromyography (showing continuous motor unit activity), and exclusion of mimics like multiple sclerosis [1][2][13]. First-line treatment includes GABA-enhancing agents (e.g., diazepam, baclofen) and immunotherapy (e.g., IVIg) [2][3][7][13].
Burden
Progressive disability: 65% require mobility aids; chronic pain/anxiety impair quality of life [5][13][18].
Mortality: ~10% risk of sudden death from respiratory failure or autonomic crises [5][13].
Healthcare utilization: Frequent falls (risk of fractures), 10% require ICU care for spasms [5][13][18].
Categories: rare endocrine diseases, rare neurological diseases
Research Papers
47 drug discovery papers about Classic stiff person syndrome, with 2 first-in-class and 1 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
47 drug discovery papers about Classic stiff person syndrome, with 2 first-in-class and 1 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
2026-07-28 | Phenotypic Spectrum, Diagnostic Challenges, and Clinical Outcomes in Stiff Person Syndrome: A Single-Center Case Series
Introduction: Stiff-Person Syndrome (SPS) is a rare autoimmune neurological disorder characterized by progressive muscle rigidity and painful spasms, primarily affecting axial and proximal musculature. Its diagnosis can be challenging due to clinical overlap with other neurological conditions such as spasticity, dystonia, or functional movement disorders. The detection of antibodies against glutamic acid decarboxylase (anti-GAD) is a key biomarker that supports diagnosis. Methods: Two clinical cases of patients with manifestations consistent with classic SPS are described, and were evaluated in a specialized neurology service. Both patients underwent detailed clinical assessment, complementary studies, and serum testing for anti-GAD antibodies. Results: Both patients presented with progressive rigidity and fluctuating muscle spasms, predominantly involving axial musculature. After an extensive diagnostic workup, elevated anti-GAD antibody titers were documented in both cases, confirming the diagnosis of classic SPS. Treatment with medications enhancing GABAergic neurotransmission was associated with significant clinical improvement, evidenced by reduced rigidity and the decreased frequency of spasms. Conclusions: These cases highlight the importance of considering SPS in the differential diagnosis of progressive rigidity syndromes. Identification of anti-GAD antibodies is essential for diagnostic confirmation, and treatment that aims to enhance GABAergic neurotransmission can significantly improve symptoms and patient functionality.
2026-06-08 | Graph-Theoretical Approach for Predicting Physicochemical Properties of Stiff-Person Syndrome Drugs.
This work applies quantitative structure-property relationship analysis to examine molecular characteristics linked to stiffness person syndrome (SPS), a rare neurological condition marked by persistent muscle rigidity and spasmodic episodes. Topological indices such as Zagreb indices and their modification are employed to examine their correlations with key physicochemical properties. Linear, quadratic, exponential growth, and power curve fitting models are applied to identify the best correlations, focusing on the maximum F-statistic and the coefficient of determination R2. Furthermore, heatmap-based correlation analysis is performed to visually quantify the strength and direction of correlations between the calculated topological indices and selected physicochemical parameters. In addition to classical regression techniques, gradient boosting, a powerful ensemble machine learning method, is utilized to enhance predictive accuracy and evaluate the contribution of each descriptor toward property estimation. Additionally, M-polynomials are calculated, and their corresponding graphs are plotted to assess the structural features of potential therapeutic agents. The findings offer significant insights into the role of graph-theoretical methods in drug discovery, advancing the computational design of targeted treatments for SPS.
2026-04-24 | Stiff person syndrome: an overview.
BACKGROUND: Stiff-person syndrome (SPS) and stiff-person spectrum disorders (SPSD) are rare, immune-mediated neurological conditions characterized by progressive muscle rigidity, painful spasms, exaggerated startle responses, and substantial functional and psychosocial morbidity. Clinical heterogeneity, frequent diagnostic delay, and evolving immunopathogenic insights continue to complicate diagnosis and management. METHODS: This narrative review synthesizes current evidence on the epidemiology, clinical phenotypes, immunopathogenesis, diagnostic strategies, therapeutic approaches, monitoring tools, and psychosocial impact of SPS and SPSD. Evidence from randomized controlled trials, cohort studies, systematic reviews, and recent advances in immunotherapy is integrated, with attention to both adult- and pediatric-onset disease. RESULTS: Classic SPS is most commonly associated with high-titer antibodies against glutamic acid decarboxylase 65 and presents with axial and proximal limb rigidity, stimulus-sensitive spasms, hyperlordosis, and gait impairment. The SPS spectrum includes stiff limb syndrome, SPS-plus, progressive encephalomyelitis with rigidity and myoclonus, paraneoplastic SPS, and seronegative forms, each with distinct clinical and immunological profiles. Impaired GABAergic inhibition represents a central pathophysiological mechanism, although the direct pathogenic role of anti-glutamic acid decarboxylase antibodies remains debated. Diagnosis relies on characteristic clinical features, targeted autoantibody testing, and neurophysiological evidence of continuous motor unit activity. Management is anchored in symptomatic GABAergic agents and immunomodulatory therapies, with intravenous immunoglobulin supported by randomized trial evidence. Emerging treatments—including B-cell–depleting therapies, plasma exchange, autologous hematopoietic stem cell transplantation, neonatal Fc receptor blockade, and chimeric antigen receptor T-cell therapy—offer potential benefit in refractory disease. Standardized clinical scales are essential for monitoring disease burden and treatment response.
2025-11-03 | Botulinum toxin as a potential adjunct therapy in stiff person syndrome spectrum disorders.
Stiff person syndrome spectrum disorders (SPSD) are a disabling group of immune-mediated disorders that most commonly cause progressive rigidity and painful spasms. Botulinum neurotoxin (BoNT) has anecdotally improved SPSD symptoms, though evidence regarding treatment strategy and clinical efficacy is scarce. To characterize the location, frequency, dosage, and clinical response to BoNT injections in patients with SPSD. We conducted a retrospective observational cohort study. SPSD patients who received BoNT treatments between August 2018 and February 2024 were included. Detailed information about the injections (formulation, dose, muscle), subjective patient-reported response, and concurrent therapies was recorded and compared between the first, third, and eighth BoNT visits. Thirty-seven SPSD patients were included. The majority had classic SPS (83.8%), were female (67.7%), white (78.4%), and on immune therapies (70.3%). The paraspinal muscles, hip flexors, distal leg flexors, and shoulder girdle muscles were most frequently injected. Supramaximal total doses up to 980 units of BoNT were used safely. The most common side effect was transient worsening of pain/spasms, which resolved with peak dose effect. Subjective clinical response was positive, with a median patient-reported 5-point Likert rating of 4, 5, and 5 after visits 1, 3, and 8. BoNT may be an effective and durable adjunctive symptomatic therapy for people with SPSD with targeted muscle selection based on specific symptomatology. Injections into multiple body regions and use of supramaximal dosages may be required for adequate symptom control in this patient population. As our data lacked objective measures and relied on semiqualitative self-reported patient responses, conclusions about the utility of BoNT are limited and randomized placebo-controlled trials are needed to evaluate the impact of BoNT on improving quality of life, mobility, and burden of systemic symptomatic treatment.
2025-08-08 | Exploring if Longitudinal Changes on PET Imaging Can Serve as a Biomarker for Stiff Person Syndrome Spectrum Disorders.
To identify metabolic patterns in the brain and musculoskeletal system of stiff person syndrome spectrum disorders (SPSD) patients over time using PET imaging and evaluate the impact of immune therapy on metabolic activity as a surrogate for treatment response. This observational study at the Johns Hopkins SPS Center of Excellence included adults (≥ 18 years) diagnosed with classic SPS, partial SPS, SPS plus, or PERM, who were treated from 2009 to 2023. Participants underwent at least two whole-body and/or dedicated brain PET scans. Brain PET analysis utilized NeuroQ v3.8 software to generate standardized Z-scores for 47 distinct brain regions, assessed by expert nuclear medicine radiologists. Patient demographics, antibody types, immune therapies, and symptomatic treatments were assessed. Eighteen patients met inclusion criteria (10 SPS plus, 6 classic SPS, 2 PERM), with a mean age of 50.7 (SD 8.5) years; 77.8% were female and 50.0% were Black/African American. Hypermetabolic activity and hypometabolism were both seen over time in the brain and the musculoskeletal system. Two patients starting immune therapy in between PET scans demonstrated improvement in brain but not body PET findings. The study findings indicate that PET imaging abnormalities are present over time and appear to have regional patterns that are common among phenotypes. Additionally, starting immune therapy between scans appears to correlate with stabilization or improvement in brain PET abnormalities, though this was less clear in body PET scans. PET scans have the potential to be an imaging biomarker in SPSD, but future studies are needed to validate this.
2026-07-28 | Phenotypic Spectrum, Diagnostic Challenges, and Clinical Outcomes in Stiff Person Syndrome: A Single-Center Case Series
Introduction: Stiff-Person Syndrome (SPS) is a rare autoimmune neurological disorder characterized by progressive muscle rigidity and painful spasms, primarily affecting axial and proximal musculature. Its diagnosis can be challenging due to clinical overlap with other neurological conditions such as spasticity, dystonia, or functional movement disorders. The detection of antibodies against glutamic acid decarboxylase (anti-GAD) is a key biomarker that supports diagnosis. Methods: Two clinical cases of patients with manifestations consistent with classic SPS are described, and were evaluated in a specialized neurology service. Both patients underwent detailed clinical assessment, complementary studies, and serum testing for anti-GAD antibodies. Results: Both patients presented with progressive rigidity and fluctuating muscle spasms, predominantly involving axial musculature. After an extensive diagnostic workup, elevated anti-GAD antibody titers were documented in both cases, confirming the diagnosis of classic SPS. Treatment with medications enhancing GABAergic neurotransmission was associated with significant clinical improvement, evidenced by reduced rigidity and the decreased frequency of spasms. Conclusions: These cases highlight the importance of considering SPS in the differential diagnosis of progressive rigidity syndromes. Identification of anti-GAD antibodies is essential for diagnostic confirmation, and treatment that aims to enhance GABAergic neurotransmission can significantly improve symptoms and patient functionality.
2026-06-08 | Graph-Theoretical Approach for Predicting Physicochemical Properties of Stiff-Person Syndrome Drugs.
This work applies quantitative structure-property relationship analysis to examine molecular characteristics linked to stiffness person syndrome (SPS), a rare neurological condition marked by persistent muscle rigidity and spasmodic episodes. Topological indices such as Zagreb indices and their modification are employed to examine their correlations with key physicochemical properties. Linear, quadratic, exponential growth, and power curve fitting models are applied to identify the best correlations, focusing on the maximum F-statistic and the coefficient of determination R2. Furthermore, heatmap-based correlation analysis is performed to visually quantify the strength and direction of correlations between the calculated topological indices and selected physicochemical parameters. In addition to classical regression techniques, gradient boosting, a powerful ensemble machine learning method, is utilized to enhance predictive accuracy and evaluate the contribution of each descriptor toward property estimation. Additionally, M-polynomials are calculated, and their corresponding graphs are plotted to assess the structural features of potential therapeutic agents. The findings offer significant insights into the role of graph-theoretical methods in drug discovery, advancing the computational design of targeted treatments for SPS.
2026-04-24 | Stiff person syndrome: an overview.
BACKGROUND: Stiff-person syndrome (SPS) and stiff-person spectrum disorders (SPSD) are rare, immune-mediated neurological conditions characterized by progressive muscle rigidity, painful spasms, exaggerated startle responses, and substantial functional and psychosocial morbidity. Clinical heterogeneity, frequent diagnostic delay, and evolving immunopathogenic insights continue to complicate diagnosis and management. METHODS: This narrative review synthesizes current evidence on the epidemiology, clinical phenotypes, immunopathogenesis, diagnostic strategies, therapeutic approaches, monitoring tools, and psychosocial impact of SPS and SPSD. Evidence from randomized controlled trials, cohort studies, systematic reviews, and recent advances in immunotherapy is integrated, with attention to both adult- and pediatric-onset disease. RESULTS: Classic SPS is most commonly associated with high-titer antibodies against glutamic acid decarboxylase 65 and presents with axial and proximal limb rigidity, stimulus-sensitive spasms, hyperlordosis, and gait impairment. The SPS spectrum includes stiff limb syndrome, SPS-plus, progressive encephalomyelitis with rigidity and myoclonus, paraneoplastic SPS, and seronegative forms, each with distinct clinical and immunological profiles. Impaired GABAergic inhibition represents a central pathophysiological mechanism, although the direct pathogenic role of anti-glutamic acid decarboxylase antibodies remains debated. Diagnosis relies on characteristic clinical features, targeted autoantibody testing, and neurophysiological evidence of continuous motor unit activity. Management is anchored in symptomatic GABAergic agents and immunomodulatory therapies, with intravenous immunoglobulin supported by randomized trial evidence. Emerging treatments—including B-cell–depleting therapies, plasma exchange, autologous hematopoietic stem cell transplantation, neonatal Fc receptor blockade, and chimeric antigen receptor T-cell therapy—offer potential benefit in refractory disease. Standardized clinical scales are essential for monitoring disease burden and treatment response.
2025-11-03 | Botulinum toxin as a potential adjunct therapy in stiff person syndrome spectrum disorders.
Stiff person syndrome spectrum disorders (SPSD) are a disabling group of immune-mediated disorders that most commonly cause progressive rigidity and painful spasms. Botulinum neurotoxin (BoNT) has anecdotally improved SPSD symptoms, though evidence regarding treatment strategy and clinical efficacy is scarce. To characterize the location, frequency, dosage, and clinical response to BoNT injections in patients with SPSD. We conducted a retrospective observational cohort study. SPSD patients who received BoNT treatments between August 2018 and February 2024 were included. Detailed information about the injections (formulation, dose, muscle), subjective patient-reported response, and concurrent therapies was recorded and compared between the first, third, and eighth BoNT visits. Thirty-seven SPSD patients were included. The majority had classic SPS (83.8%), were female (67.7%), white (78.4%), and on immune therapies (70.3%). The paraspinal muscles, hip flexors, distal leg flexors, and shoulder girdle muscles were most frequently injected. Supramaximal total doses up to 980 units of BoNT were used safely. The most common side effect was transient worsening of pain/spasms, which resolved with peak dose effect. Subjective clinical response was positive, with a median patient-reported 5-point Likert rating of 4, 5, and 5 after visits 1, 3, and 8. BoNT may be an effective and durable adjunctive symptomatic therapy for people with SPSD with targeted muscle selection based on specific symptomatology. Injections into multiple body regions and use of supramaximal dosages may be required for adequate symptom control in this patient population. As our data lacked objective measures and relied on semiqualitative self-reported patient responses, conclusions about the utility of BoNT are limited and randomized placebo-controlled trials are needed to evaluate the impact of BoNT on improving quality of life, mobility, and burden of systemic symptomatic treatment.
2025-08-08 | Exploring if Longitudinal Changes on PET Imaging Can Serve as a Biomarker for Stiff Person Syndrome Spectrum Disorders.
To identify metabolic patterns in the brain and musculoskeletal system of stiff person syndrome spectrum disorders (SPSD) patients over time using PET imaging and evaluate the impact of immune therapy on metabolic activity as a surrogate for treatment response. This observational study at the Johns Hopkins SPS Center of Excellence included adults (≥ 18 years) diagnosed with classic SPS, partial SPS, SPS plus, or PERM, who were treated from 2009 to 2023. Participants underwent at least two whole-body and/or dedicated brain PET scans. Brain PET analysis utilized NeuroQ v3.8 software to generate standardized Z-scores for 47 distinct brain regions, assessed by expert nuclear medicine radiologists. Patient demographics, antibody types, immune therapies, and symptomatic treatments were assessed. Eighteen patients met inclusion criteria (10 SPS plus, 6 classic SPS, 2 PERM), with a mean age of 50.7 (SD 8.5) years; 77.8% were female and 50.0% were Black/African American. Hypermetabolic activity and hypometabolism were both seen over time in the brain and the musculoskeletal system. Two patients starting immune therapy in between PET scans demonstrated improvement in brain but not body PET findings. The study findings indicate that PET imaging abnormalities are present over time and appear to have regional patterns that are common among phenotypes. Additionally, starting immune therapy between scans appears to correlate with stabilization or improvement in brain PET abnormalities, though this was less clear in body PET scans. PET scans have the potential to be an imaging biomarker in SPSD, but future studies are needed to validate this.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
2 orphan drug designations for Classic stiff person syndrome.
2 orphan drug designations for Classic stiff person syndrome.
Drug | Therapy type | Regulator | Orphan designation | Approval | Sponsor |
|---|---|---|---|---|---|
autologous T cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19 | cell therapies | FDA | 2024-08-21 | — | Kyverna Therapeutics, Inc |
Intravenous immune globulin (human) 10% | antibodies | FDA | 2008-07-31 | — | Octapharma USA, Inc. |
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI's forecasts to outperform average preclinical success rates. Whether you're expanding your R&D pipeline, evaluating a partnership, or simply have a question — we'd love to hear from you.